title: [Experience of Lucentis use in patients with wet age-related macular degeneration].
abstract: This article provides information about development and introduction of regional standard of specialized medical care for patients with neovascular age-related macular degeneration in medical practice in Tumen region. It discovered new opportunities for improvement of ophthalmologic care in the region.
authors.forename: I G
authors.initials: IG
authors.lastname: Dolgova
authors.forename: T N
authors.initials: TN
authors.lastname: Malishevskaia
authors.forename: I M
authors.initials: IM
authors.lastname: Rybina
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D020256:Choroidal Neovascularization / Q000150:complications / Q000503:physiopathology; D019468:Disease Management; D017598:Efficiency, Organizational; D005260:Female; D006801:Humans; D056965:Injections, Intraocular / Q000379:methods; D008297:Male; D008875:Middle Aged; D011357:Product Line Management / Q000458:organization & administration*; D000069579:Ranibizumab; D012800:Siberia; D059039:Standard of Care; D041623:Tomography, Optical Coherence / Q000379:methods*; D016896:Treatment Outcome; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab